OUP user menu

Corrigendum to: ‘Guidelines for the management of atrial fibrillation’ [European Heart Journal (2010) 31, 2369–2429 and EP-Europace (2010) 12, 1360–1420]

A. John Camm, Paulus Kirchhof, Gregory Y.H. Lip, Ulrich Schotten, Irene Savelieva, Sabine Ernst, Isabelle C. Van Gelder, Nawwar Al-Attar, Gerhard Hindricks, Bernard Prendergast, Hein Heidbuchel, Ottavio Alfieri, Annalisa Angelini, Dan Atar, Paolo Colonna, Raffaele De Caterina, Johan De Sutter, Andreas Goette, Bulent Gorenek, Magnus Heldal, Stefan H. Hohloser, Philippe Kolh, Jean-Yves Le Heuzey, Piotr Ponikowski, Frans H. Rutten
DOI: http://dx.doi.org/10.1093/eurheartj/ehq512 1172 First published online: 5 April 2011

The European Society of Cardiology and the publishers regret that a table containing errors was published in these guidelines. Table 15 (page 2399 in the European Heart Journal and page 1390 in EP-Europace) should be replaced by the table below (the areas that have been corrected are identified by blue type).

View this table:
Table 15

Drugs for rate control

Embedded Image
  • ER = extended release formulations; N/A = not applicable.

  • aOnly in patients with non-permanent atrial fibrillation.

Also, Figure 9 (page 2400 in the European Heart Journal and page 1391 in EP-Europace) should have shown under ‘Inactive’ that the following rate control drugs are also allowed: β-blocker, diltiazem, and verapamil.

The authors wish to apologize that these errors were not identified earlier. The corrected table and figure appear in the online editions of the European Heart Journal and EP-Europace.

View Abstract